Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA decisions to watch from October 3-5 include the approval of a rival to a fast-selling Pfizer heart drug, a lung cancer medicine, and an addition to Vertex's cystic fibrosis business. Prime is narrowing its gene editing research and partnering with Bristol Myers, while Lilly plans to invest $4.5 billion in advanced drug manufacturing. IGM has laid off staff in an autoimmune pivot, Metsera is ramping up obesity drug supply, and other biotechs are focusing on T cell engagers for treating inflammatory conditions. The newsletter also covers recent developments in gene therapy, including stem cells reversing diabetes in a world-first case and the slow adoption of gene therapy for sickle cell disease. Biopharma Dive provides insights into the latest news and trends in biotech and pharma, from clinical trials to drug pricing and research partnerships.